U.S. markets closed

ALR Technologies Inc. (ALRT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0458-0.0007 (-1.51%)
At close: 03:32PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0465
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0458 - 0.0481
52 Week Range0.0450 - 0.0750
Avg. Volume101,675
Market Cap24.856M
Beta (5Y Monthly)2.71
PE Ratio (TTM)N/A
EPS (TTM)-0.0130
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALRT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Medtronic plcOne of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
    Fair Value
    Economic Moat
    9 days agoMorningstar
View more
  • GlobeNewswire

    ALR Technologies Releases Select Results from Market Research on Diabetic Pet Industry; Market Demand High for Innovation

    GluCurve is the world’s first continuous glucose monitor (CGM) for diabetic dogs and catsGluCurve eliminates need for manual, costly and cumbersome “glucose curves” that are today’s standard of care2017 AVMA Report shows between 28,000-32,000 veterinary practices in U.S.97% of DVM survey respondents indicated they’d use a pet CGM system to diagnose and manage diabetic dogs and cats as soon as available SINGAPORE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB

  • GlobeNewswire

    ALR Technologies Releases New Website and Investor Presentation

    SINGAPORE, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, today announces that the Company has released a new investor presentation that can be viewed at The Company invites investors and interested parties to explore the recently redesigned corporate website. “ALRT is at an inflection point, moving forward with high-level negotiations and due diligence processes that will be transformational to

  • GlobeNewswire

    ALR Technologies Advances Partnership Discussions with Two Global Animal Health Pharmaceutical Companies

    SINGAPORE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- ALR Technologies SG Pte. Ltd. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, announces today the advancement in partnership talks on the GluCurve Pet CGM with two key pharmaceutical companies in animal health. Subject to further due diligence and financial negotiations, one of the two will be selected as a strategic partner through purchasing a stake in the GluCurve Pet CGM. Joe Stern, Head of Animal Health at ALRT commented